Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

• Status: Terminated
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine if aclerastide (DSC127) is effective in increasing incidence of complete wound closure up to 10 weeks confirmed 2 weeks later, compared with vehicle (gel without active ingredient) and compared with a standard-of-care gel, in subjects with diabetes mellitus (DM) who have chronic Wagner Grade 1 or 2 diabetic foot ulcers, 0.75 - 6cm2 in size.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Derma Sciences, Inc.; Integra LifeSciences Corporation
• Collaborator: Integrium

Criteria

Inclusion Criteria:

• Male or female ambulatory subject age ≥18 years at the time of informed consent

• Has type 1 or type 2 DM under metabolic control as confirmed by a glycosylated hemoglobin (HbA1c) of ≤12% and a serum creatinine level of ≤3mg/dL

• At Screening and Baseline (prior to randomization), subject has at least one ulcer that fulfills all of the following criteria:

• present for ≥1 month and ≤1 year

• Partial- or full- thickness and not involving bone, tendon, or capsule (probing to tendon or capsule), i.e. Wagner Grade 1 or 2.

• Has no sign of infection or osteomyelitis

• Plantar neuropathic ulcer - predominately be on the plantar surface (i.e. weight bearing) of the foot to ensure adequate off-loading and may include the toes

• Size of the target ulcer must be 0.75-6 cm2.

• Target ulcer must be non-healing as defined as <30% reduction in area in response to standard of care during the Screening Period

• If more than one ulcer is present that meets the inclusion criteria, the largest one will be considered the target ulcer

• If there are two ulcers of the same size that meet all criteria, the one with the higher Wagner Grade will be considered the target ulcer

• If there are two ulcers of the same size and the same Wagner Grade, the one present for the longest qualifying time will be the target ulcer.

• Non-target ulcers will also be treated according to standard of care (Acute Charcot Neuroarthropathy of the foot with the target ulcer must be excluded)

• Has an ankle brachial index (ABI) ≥0.7 on the foot with the target ulcer.

• Has an assessment of the baseline level of neuropathy of the foot using Semmes-Weinstein filaments.

• A female subject of childbearing potential must have a negative serum pregnancy test at the time of Screening.

• A female subject of childbearing potential must be willing to use a medically acceptable method of birth control, such as Essure®, hormonal contraception (oral pills, implantable device, or skin patch), intrauterine device, tubal ligation, or double barrier throughout the study. A female subject of childbearing potential who practices abstinence is not required to employ birth control.

• Has the ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment in the study or initiation of study procedures

Exclusion Criteria:

• Has a known hypersensitivity to any of the investigational drug or vehicle or standard of care gel components

• Has been exposed to any investigational agent within 30 days of entry into the study

• A female who is pregnant or nursing

• Has active malignant disease of any kind except for basal cell carcinoma (of the skin). A subject, who has had a malignant disease in the past, was treated and is currently disease-free, may be considered for study entry.

• Has a hemoglobin of less than 8.5 gm/dL.

• Transaminase levels greater than 3 × normal

• Is receiving hemodialysis or chronic ambulatory peritoneal dialysis (CAPD) therapy

• Has had prior radiation therapy to any part of the foot with the target ulcer under study

• Use of systemic corticosteroids and immunosuppressants (within the 8 weeks prior to screening)

• Has an ulcer primarily ischemic in etiology

• Has sickle-cell anemia, Reynaud's, or peripheral vascular disease

• Has received a biologic agent, growth factor, or skin equivalents (Regranex®, Apligraft, or Dermagraft), in the past 30 days

• Has a target ulcer which is determined to be clinically infected and requires antimicrobials. Any antibiotic therapy must be completed or discontinued at Screening.

• Has a Wagner Grade 3 or higher DFU, deep abscess, or gangrene

• Has uncontrolled hypertension, in the opinion of the Investigator.

• Any other finding, which in the opinion of the Investigator, may interfere with the assessment of the product or participation of the patient in the study.